Granahan Investment Management LLC Has $8.04 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Granahan Investment Management LLC reduced its holdings in Kiniksa Pharmaceuticals by 21.9%, selling 101,216 shares and currently owning approximately 0.50% of the company valued at $8,038,000.
• Several major investors increased their stakes, with Deutsche Bank AG boosting its position by 177.1% and purchasing additional shares worth approximately $8,762,000 in the first quarter.
• Analysts have a favorable outlook, with six analysts rating Kiniksa Pharmaceuticals as a "Buy" and an average target price of $41.17, reflecting increasing confidence in the company's stock performance.

Granahan Investment Management LLC cut its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 21.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 361,894 shares of the company's stock after selling 101,216 shares during the period. Granahan Investment Management LLC owned approximately 0.50% of Kiniksa Pharmaceuticals International worth $8,038,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Corebridge Financial Inc. boosted its position in shares of Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after buying an additional 549 shares during the period. GAMMA Investing LLC lifted its position in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Sound View Wealth Advisors Group LLC lifted its position in Kiniksa Pharmaceuticals International by 4.0% in the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after purchasing an additional 568 shares during the period. Martingale Asset Management L P lifted its position in Kiniksa Pharmaceuticals International by 1.3% in the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after purchasing an additional 640 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kiniksa Pharmaceuticals International by 6.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock worth $432,000 after purchasing an additional 1,380 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark Ragosa sold 18,889 shares of the business's stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.89, for a total transaction of $621,259.21. Following the completion of the sale, the chief financial officer directly owned 27,009 shares of the company's stock, valued at $888,326.01. This represents a 41.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 562,271 shares of company stock worth $18,716,309. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Trading Down 2.5%

NASDAQ:KNSA traded down $0.93 during mid-day trading on Wednesday, hitting $35.93. The company's stock had a trading volume of 115,407 shares, compared to its average volume of 666,421. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of 900.35 and a beta of 0.20. The stock has a fifty day moving average of $31.32 and a 200-day moving average of $26.77. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $37.25.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on KNSA shares. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Finally, Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.